General Anesthesia Drugs Market Statistics - 2031
The global general anesthesia drugs market size was valued at $5.4 billion in 2021, and is projected to reach $7.7 billion by 2031, growing at a CAGR of 3.5% from 2022 to 2031. The general anesthesia drug is the induction and maintenance of state of unconsciousness with the absence of pain sensation. It is basically induced state of unconsciousness accompanied by partial or complete loss of protective reflexes. It is administered in combination with medication through intravenous or inhalation route. Propofol, etiomide, ketamine are some intravenous general anesthetic drugs and sevoflurane desflurane are inhalation anesthesia drugs. General anesthesia is used in various cardiac surgeries, hip and knee replacement surgeries, cancer surgeries, and gastro-intestinal surgeries.
The growth of the global general anesthesia drugs market share is majorly driven by increase in prevalence of chronic disease such as cancer, cardiovascular disease, osteoarthritis; rise in demand for inhalation anesthesia; increase in funding from private & government organizations for development of pharmaceutical manufacturing segments; and rise in R&D activities for formulation of general anesthesia drug. In addition, according to World Health Organization, in 2022, it was reported that cardiovascular disease is the most common cause of death, across the globe. Patients with coronary heart disease, heart failure, atrial fibrillation, are more prone to open heart surgery procedure. The open heart surgery is conducted under general anesthesia. This factor propels the growth of the market.
Furthermore, increase in number of approval for general anesthesia drug drives growth of the market. For instance, in September 2020, U.S Food and Drug Administration (FDA) announced the approval for propofol injectable emulsion. It is a general intravenous anesthesia and sedation drugs, used before surgical procedure. In addition, increase in number of surgical procedure is anticipated to contribute toward growth of the general anesthesia drugs market. According to the Canadian Joint Replacement Registry (CJRR), it was reported that more than 75,000 knee replacement and 63,000 hip replacement surgeries were performed in Canada from 2019 to 2020. Moreover, increase in prevalence of geriatric population, who are more susceptible to chronic diseases, due to hormonal change and aging effect propel the growth of the market. According to the Interactive cardiovascular and thoracic surgery, in April 2022, it was reported that around 227,442 population above 70 years undergo cardiovascular procedure.
Furthermore, R&D activities in the pharmaceutical industry to formulate novel general anesthesia drug is expected to provide remunerative opportunities for expansion of the global general anesthesia drugs market during the general anesthesia drugs market forecast period. Moreover, presence of key manufacturing companies to manufacture and distribute general anesthesia drugs products and rise in expenditure on healthcare products propel the growth of the general anesthesia drugs market. For instance, in April 2020, Hikma pharmaceutical Plc, a pharmaceutical company, announced the launch of vecuronium Bromide for Injection, which is a new general anesthesia drug. Initiatives taken by government and private organizations to develop pharmaceutical industry propel the growth of the market. However, the side effect associated with general surgery such as nausea, vomiting, and allergy reaction, is expected to restrict the general anesthesia drugs market growth during the forecast period.
Global General Anesthesia Drug Segmentation
The general anesthesia drugs market is segmented on the basis of type of drug, route of administration, surgery type, end user and region. By type of drug, the market is categorized into propofol, sevoflurane, desflurane and other. Further the others are categorized into ketamine, thiopental, methohexital, etomidate, isoflurane, fospropofol. By route of administration, the market is divided into intravenous and inhalation. By surgery, the market is classified into knee and hip replacements, heart surgeries, cancer surgery, general surgery. By end user, the market is divided into hospital and ambulatory surgical centers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
Depending on type of drug, the others segment dominated the general anesthesia drugs market in 2021, and this trend is expected to continue during the forecast period, owing to increase in number of approval for general anesthesia drugs. However, the sevoflurane segment is expected to witness considerable growth during the forecast period, owing to increase in demand for inhalation anesthesia, and rise in number of key players for manufacturing of sevoflurane inhalation anesthesia drug.
By route of administration, the inhalation segment was the major contributor in 2021, and is expected to maintain its lead during the forecast period, owing to rise in number of diagnostic procedure, and increase in government support regarding the use of inhalation anesthesia. However, the intravenous anesthesia segment is expected to witness considerable growth during the forecast period, owing to increase in number of surgical procedure, such as open heart surgery.
On the basis of surgery type, the knee and hip replacements segment dominated the general anesthesia drugs market in 2021, and this trend is expected to continue during the forecast period, owing to increase in prevalence of osteoarthritis, rise in number of arthroplasty procedure, and increase in accident and sport related knee and hip injury. However, the heart surgery segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of cardiovascular disease and rise in number of open heart surgery procedure.
On the basis of end user, the hospital segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to rise in number of hospitals, and rise in expenditure by government to improve healthcare industry. However, the ambulatory segment is expected to witness considerable growth during the forecast period, due to increase in shift of patient from inpatient to outpatient surgical procedure.
North America garnered a major share in the general anesthesia drugs market size in 2021, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of chronic disease, increase in number of approval for general anesthesia drug, presence of general anesthesia drugs industry, and development in R&D activities in healthcare sector in the region. However, Asia-Pacific is expected to register highest CAGR of 4.2% from 2022 to 2031, owing to increase in prevalence of cardiovascular disease, rise in number of surgical procedure, and growth in health care expenditures.
The key players operating in the global general anesthesia drugs market include AbbVie, AstraZeneca, Avet Pharmaceuticals Inc. B. Braun Melsungen, Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, PAION AG, Par Pharmaceutical, Pfizer
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the general anesthesia drugs market analysis from 2021 to 2031 to identify the prevailing general anesthesia drugs market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the general anesthesia drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global general anesthesia drugs market trends, key players, market segments, application areas, and market growth strategies.
General Anesthesia Drugs Market Report Highlights
| Aspects | Details |
 By Type |
|
 By ROUTE OF ADMNISTRATION |
|
 By SURGERY TYPE |
|
 By END USER |
|
 By Region |
|
 Key Market Players | AstraZeneca plc, Avet Pharmaceuticals Inc, Paion AG, Baxter International Inc., B. Braun Melsungen, Fresenius SE and Co. KGaA, Pfizer Inc., Abbott Laboratories, Hikma Pharmaceuticals plc, Abbvie Inc |
Analyst Review
General anesthesia is a combination of drugs which causes controllable unconsciousness. General anesthesia is used during surgery to avoid the stimulus of pain. The factors which drive the growth of the general anesthesia drug market include increase in number of surgical procedures such as cardiac surgeries, neuro surgeries, orthopedic surgeries and others. However, the factor which restraints the growth of the general anesthesia market is risk associated with anesthetic drugs such as allergic reaction, nausea, and vomiting. Advancement in R&D activities in general anesthesia in pharmaceutical and biotechnology sector and rise in funding from government or non-government organizations to provide surgical resources, propel the growth of the market.
Further, North America is expected to witness highest growth, in terms of revenue, owing to increase in number of approval for general anesthesia drug, and development in R&D activities in healthcare sector.
Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to increase in prevalence of cardiovascular disease, rise in number of surgical procedures, and growth in healthcare expenditures.
The total market value of general anesthesia drugs market is $5,400.5 million in 2021.
The forecast period in the report is from 2022 to 2031
The market value of general anesthesia drugs Market in 2022 was $5,671 million
The base year for the report is 2021.
Yes, general anesthesia drugs companies are profiled in the report
The top companies that hold the market share in general anesthesia drugs market are AbbVie, AstraZeneca, Avet Pharmaceuticals Inc. B. Braun Melsungen, Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, PAION AG, Par Pharmaceutical, Pfizer
The key trends in the general anesthesia drugs market are increase in prevalence of chronic disease such as cancer, cardiovascular disease, osteoarthritis; rise in demand for inhalation anesthesia; increase in funding from private & government organizations for development of pharmaceutical manufacturing segments; and rise in R&D activities for formulation of general anesthesia drug.
Loading Table Of Content...
